Journal of Gastrointestinal Cancer最新文献

{"title":"Rising Incidence of Total and Early-Onset Colorectal Cancer: A Global Perspective on Burden, Risk Factors, and Projections to 2031.","authors":"Jia-Xin Nie, Qin Xie, Yan Yuan, Mei-Yuan Liu, Ji-Ke Du, Nan Li, Qing-Feng Zou","doi":"10.1007/s12029-025-01257-1","DOIUrl":"https://doi.org/10.1007/s12029-025-01257-1","url":null,"abstract":"<p><strong>Background: </strong>The occurrence of colorectal cancer in those under 50 has significantly increased in recent decades. This study assesses the burden of colorectal cancer (CRC) and early-onset colorectal cancer (EO-CRC), along with associated risk factors, using data from the Global Burden of Disease (GBD) 2021, and projects incidence and mortality rates for 2031.</p><p><strong>Methods: </strong>Data on prevalence, incidence, mortality, disability-adjusted life years (DALYs), and risk factors were retrieved from the GBD 2021. The average annual percentage changes (AAPCs) were calculated using joinpoint regression analysis, and projections to 2031 were made with Autoregressive Integrated Moving Average (ARIMA) models.</p><p><strong>Results: </strong>The number of new CRC cases globally was 2,194,143, of which EO-CRC accounted for 211,890 cases. Both CRC (AAPC 0.20) and EO-CRC (AAPC 0.99) demonstrated global increases from 1990 to 2021, with EO-CRC showing a sharper rise. The most significant increases in EO-CRC incidence, mortality, and DALYs occurred in America. Projected EO-CRC incidence and mortality rates for 2031 are 6.70 and 2.57 per 100,000 individuals, respectively. Major risk factors for CRC and EO-CRC DALYs included diets low in milk and calcium, high red meat intake, and elevated BMI.</p><p><strong>Conclusions: </strong>This study highlights the growing EO-CRC burden, particularly in America, emphasizing the need for targeted interventions to address dietary and lifestyle risk factors. Projections indicate a continued rise in EO-CRC incidence and mortality by 2031, underscoring the urgency for public health action to mitigate this trend. The occurrence of colorectal cancer in those under 50 has significantly increased globally from 1990 to 2021, with notable regional variations. Our study assesses the current burden of CRC and EO-CRC using data from the Global Burden of Disease 2021, identifies associated risk factors, and projects incidence and mortality trends through 2031 using ARIMA models. These findings offer a precise measurement of the EO-CRC burden and underscore the necessity of identifying and addressing at-risk people to effectively mitigate this escalating health concern.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"138"},"PeriodicalIF":1.6,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144317079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Efficacy and Safety of Apatinib Combined with Irinotecan in HER2-negative Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma after First-Line Treatment Failure: A Single-Arm, Single-Center Retrospective Study.","authors":"Jiajia Huang, Jianjun Peng, Ertao Zhai, Ran Wei, Chen Qian, Jialin Li, Shirong Cai, Jinping Ma","doi":"10.1007/s12029-025-01259-z","DOIUrl":"10.1007/s12029-025-01259-z","url":null,"abstract":"<p><strong>Background: </strong>In this study, the clinical efficacy and safety of apatinib combined with irinotecan in HER2-negative patients with first-line treatment failure for advanced gastric adenocarcinoma and gastroesophageal junction (GEJ) adenocarcinoma were evaluated.</p><p><strong>Methods: </strong>We performed a single-arm, retrospective study at one tertiary hospital in Guangzhou, China. Eligible patients aged 28-77 years with histologically confirmed HER2-negative advanced gastric cancer who had previously received first-line treatment were included. The patients received irinotecan (180 mg/m² intravenously once every 3 weeks) plus oral apatinib (500 mg once daily on days 1-21 of each 3-week cycle), until disease progression, unacceptable toxicity, or death. The primary endpoints were progression-free survival (PFS) and overall survival (OS), which were calculated via the Kaplan‒Meier method.</p><p><strong>Results: </strong>Between Feb 21, 2019, and Aug 14, 2023, 79 patients met the inclusion criteria. The median PFS was 3.20 months (95% CI, 1.57‒4.83), and the median OS was 7.60 months (95% CI, 5.11‒10.10). According to RECIST version 1.1, 15 patients (18.99%) achieved an objective response, and 31 patients (39.24%) achieved disease control. In terms of the safety profile, 72.2% of patients experienced treatment-emergent adverse events of any grade, among whom, 59.5% of patients experienced grade 1-2 adverse events and 12.7% of patients experienced grade 3-4 adverse events.</p><p><strong>Conclusion: </strong>Apatinib combined with irinotecan demonstrates modest efficacy with manageable safety profiles in HER2-negative patients with advanced gastric or GEJ adenocarcinoma for whom first-line treatment has failed. Further prospective studies are warranted.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"137"},"PeriodicalIF":1.6,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12170724/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144309992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Impact of Thoracic Extra-regional Lymph Node Metastasis Defined By the 12th Japanese Classification Following Definitive Radiotherapy for Esophageal Squamous Cell Carcinoma.","authors":"Masahiro Inada, Kiyoshi Nakamatsu, Junki Fukuda, Naoko Ishida, Saori Tatsuno, Takuya Uehara, Hiroshi Doi, Makoto Hosono, Yukinori Matsuo","doi":"10.1007/s12029-025-01258-0","DOIUrl":"https://doi.org/10.1007/s12029-025-01258-0","url":null,"abstract":"<p><strong>Purpose: </strong>The aim of this study was to investigate the prognostic impact of thoracic extra-regional lymph node metastasis (M1b-LYM, determined by the 12th edition of the Japanese Classification of Esophageal Cancer) in definitive radiotherapy for esophageal squamous cell carcinoma.</p><p><strong>Methods: </strong>Eighty-six consecutive patients who underwent definitive radiotherapy for esophageal squamous cell carcinoma between 2017 and 2022 at our institute were included in this retrospective study. Progression-free survival (PFS), overall survival (OS), distant metastasis (DM), and loco-regional recurrence (LR) were compared between patients with and without M1b-LYM using Kaplan-Meier or cumulative incidence function analysis.</p><p><strong>Results: </strong>Among the 86 patients, 15 had M1b-LYM metastasis (the M1b( +) group) and 71 had no M1b-LYM metastasis (the M1b(-) group). The median follow-up period was 38 months. The 2-year PFS, OS, cumulative incidence of DM, and cumulative incidence of LR for the M1b(-) group versus M1b( +) group were 41% vs 20% (p = 0.129), 58% vs 47% (p = 0.172), 31% vs 33% (p = 0.906), and 31% vs 60% (p = 0.0369), respectively. Multivariate analysis showed that M1b( +) was associated with higher LR (p = 0.0350), T stage was associated with poorer PFS (p = 0.0138), and omitting chemotherapy was associated with poorer PFS (p = 0.0160) and OS (p < 0.01).</p><p><strong>Conclusion: </strong>The presence of thoracic extra-regional lymph node metastasis was associated with poor loco-regional control but not distant metastasis or survival in esophageal squamous cell carcinoma patients after definitive radiotherapy.</p><p><strong>Trial registration number: </strong>This study was retrospectively registered on 21 June 2024 (R06-053).</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"136"},"PeriodicalIF":1.6,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response Prediction to Neoadjuvant Chemoradiotherapy in Rectal Cancer Based on Systemic Inflammatory Markers (NLR, PLR, and LMR).","authors":"Roger Beltrati Coser, Caio Sergio R Nahas, Alex Jones Flores Cassenote, Omar S T Ghani, Rafaela B B Pinheiro, Sergio Carlos Nahas, Carlos Frederico S Marques","doi":"10.1007/s12029-025-01255-3","DOIUrl":"https://doi.org/10.1007/s12029-025-01255-3","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to evaluate whether systemic inflammatory markers-neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR)-can predict tumor response to neoadjuvant chemoradiotherapy (nCRT) in patients with rectal cancer.</p><p><strong>Methods: </strong>A retrospective, single-center study included 396 patients with biopsy-proven rectal cancer (clinical stage T2-4NxM0 or any T N + M0) treated with curative intent. All patients underwent standardized nCRT, followed by either radical surgery with total mesorectal excision (TME) or non-operative management in cases of sustained complete clinical response (cCR). Pre-treatment NLR, PLR, and LMR were calculated from baseline blood counts. Tumor response was categorized using tumor regression grade (TRG): TRG 0 (complete response), TRG 1 (almost complete), TRG 2 (partial), and TRG 3 (no response).</p><p><strong>Results: </strong>Incomplete responders (TRG 1-3) had higher NLR (p < 0.001), PLR (p = 0.002), and carcinoembryonic antigen (CEA, p < 0.001), and were more frequently male (p = 0.021). Complete responders (TRG 0) were more associated with higher LMR (p < 0.001), elevated hemoglobin levels (p = 0.049), more comorbidities (p = 0.001), and greater use of antihypertensives (p = 0.012) and antiplatelet/anticoagulant drugs (p = 0.045). Risk estimates of incomplete response were as follows: NLR > 2.08 (RR 2.30, 95% CI 1.60-3.31), PLR > 129.36 (RR 1.79, 95% CI 1.25-2.05), and LMR > 2.67 (RR 0.42, 95% CI 0.26-0.66).</p><p><strong>Conclusion: </strong>Pre-treatment NLR, PLR, and LMR are predictors of response to nCRT in patients with rectal cancer. An NLR > 2.08 is an independent predictor of incomplete response to nCRT. These findings contribute a cost-effective and readily available tool to the rectal cancer management arsenal.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"134"},"PeriodicalIF":1.6,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144275085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiofrequency Ablation Technology in Liver Malignancies: A Systematic Review of Economic Evaluations.","authors":"Amirreza Taherkhani, Hoornaz Molana, Mahsa Taremi, Ghader Mohammadnezhad","doi":"10.1007/s12029-025-01256-2","DOIUrl":"10.1007/s12029-025-01256-2","url":null,"abstract":"<p><strong>Background: </strong>Liver malignancies, including hepatocellular carcinoma (HCC), present significant treatment challenges, with limited curative options available. Radiofrequency ablation (RFA) has emerged as a minimally invasive therapeutic approach for early-stage HCC, offering comparable survival benefits to surgical resections in some patients. However, the economic implications of RFA relative to other treatment modalities remain a critical factor in decision-making. This study systematically reviews economic evaluations of RFA to assess its viability in managing liver malignancies.</p><p><strong>Methods: </strong>A systematic review was conducted following the PRISMA guidelines. Databases, including PubMed, Scopus, Web of Science, and Google Scholar, were searched for economic evaluations of RFA published from 2015 onwards. Eligible studies compared RFA with other curative and palliative treatments, focusing on health-related economic outcomes. The primary outcome of the included studies was the incremental cost-effectiveness ratio (ICER).</p><p><strong>Results: </strong>Ten studies met the inclusion criteria, covering diverse healthcare systems and cost-effectiveness models. The results indicated that RFA is generally more cost-effective than percutaneous ethanol injection [incremental cost: $ - 917, incremental effectiveness: 0.34, ICER: $ - 2675] and laparoscopic hepatectomy [incremental costs: ¥ - 4702, incremental effectiveness: 0] but less cost-effective than microwave ablation [ICER: dominated], liver resection, and transplantation [ICER: between $23,916 and $113,530/QALY] at higher willingness-to-pay thresholds. Comparisons with stereotactic body radiotherapy and surgery yielded mixed results.</p><p><strong>Conclusions: </strong>RFA is a cost-effective treatment for small HCC tumors, particularly in resource-limited settings. However, its cost-effectiveness declines with increasing tumor size compared to liver transplantation. Further real-world economic evaluations and modeling studies are needed to confirm its affordability across different healthcare settings.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"135"},"PeriodicalIF":1.6,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144275084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Prehabilitation in Major Gastrointestinal Oncological Surgery: a Systematic Review.","authors":"Reshma Ambulkar, Aditya Kunte, Sohan Lal Solanki, Veer Thakkar, Bhakti Deshmukh, Pankaj Singh Rana","doi":"10.1007/s12029-025-01196-x","DOIUrl":"10.1007/s12029-025-01196-x","url":null,"abstract":"<p><strong>Background: </strong>Patients undergoing major gastrointestinal oncologic surgeries often present with frailty, sarcopenia, anemia, and comorbidities that reduce physiological reserves and impair recovery. Prehabilitation is a proactive, multidisciplinary approach designed to optimize patient's health before surgery, thereby enhancing their capacity to tolerate surgical stress. Evidence indicates that prehabilitation can lead to shorter hospital stays, reduced intensive care admissions, a lower incidence of postoperative complications, and improved long-term quality of life.</p><p><strong>Methods: </strong>This systematic review is aimed at comprehensively evaluating the current evidence on prehabilitation in gastrointestinal and hepatopancreatobiliary (HPB) surgeries, examining its components, mechanisms of benefit, and barriers to implementation. It also explores the effectiveness of multimodal prehabilitation programs and highlights areas for future research. A systematic search of \"PubMed/MEDLINE,\" \"Google Scholar,\" \"Scopus,\" \"Cochrane Library,\" \"ClinicalTrials.gov,\" and \"POPLINE\" databases was conducted using a combination of Medical Subject Headings (MeSH) and keywords, including Prehabilitation, Anemia Correction, Nutrition Therapy, Physical Exercise, Gastrointestinal Cancer Surgeries, Hepato-Pancreato-Biliary Surgeries, Rehabilitation, and Postoperative Outcomes. Studies involving gastrointestinal cancer patients undergoing surgery, published between 1960 and June 2024, were included.  RESULTS: Multimodal prehabilitation programs demonstrated significant improvements in functional capacity, reductions in postoperative complications, shorter lengths of stay, and enhanced recovery. However, the strength of evidence varied by cancer type, with robust data supporting prehabilitation in colorectal surgeries and more limited evidence for HPB and upper gastrointestinal surgeries. Home-based programs showed mixed results, with adherence challenges potentially undermining their effectiveness. Inpatient supervised programs were more effective but associated with higher costs.</p><p><strong>Conclusion: </strong>Prehabilitation holds promise as a transformative strategy in the perioperative care of gastrointestinal cancer patients. While it improves functional and clinical outcomes, significant barriers such as implementation costs, patient adherence, and variability in program design must be addressed. Future research should focus on tailoring prehabilitation for different cancer types, developing cost-effective models, and conducting high-quality trials to establish standardized guidelines. Integrating prehabilitation into routine clinical practice can significantly enhance surgical outcomes and patient quality of life.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"133"},"PeriodicalIF":1.6,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12158854/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144275075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prehabilitation Reduces Occurrence of Anastomotic Leaks After Esophagectomy-A Retrospective Cohort Analysis and Meta-analysis.","authors":"Alissa Jell, Alexandra Dusi, Marcus Feith, Jeannine Bachmann, Dirk Wilhelm, Marc Martignoni, Ekin Ihsan Demir, Helmut Friess, Stephan Schorn","doi":"10.1007/s12029-025-01213-z","DOIUrl":"10.1007/s12029-025-01213-z","url":null,"abstract":"<p><strong>Background: </strong>Esophageal anastomotic leaks (EAL) after esophagectomy strongly increase postoperative mortality and morbidity. Identifying, addressing, and improving risk factors are pivotal. In this article, we conducted a systematic review with meta-analysis, comparing findings with our 13-year experience in a German high-volume esophageal surgery center.</p><p><strong>Methods: </strong>Databases of Pubmed, Scopus, and Cochrane were systematically screened for publications prior to 2025, and all patients undergoing esophageal resection surgery from 2010 to 2022 were analyzed for EAL occurrence, incorporating the review data into our analysis.</p><p><strong>Results: </strong>Among 14,163 studies screened, 202 were included, with 123 studies providing sufficient information on risk factors' impact on EAL. Our patient register revealed 144 out of 787 with EAL. Cardiopulmonary factors such as hypertension (RR 1.44; p = 0.0004), coronary artery disease (RR 1.28; p = 0.0004), heart insufficiency (RR 1.56; p = 0.05), peripheral artery disease (RR 1.65; p = 0.0009), pulmonary disease (RR 1.5; p = 0.01), COPD (RR 1.39; p = 0.13), renal insufficiency (RR 1.61; p = 0.03), diabetes mellitus (RR 1.51; p < 0.00001), obesity (BMI > 25; RR 1.31; p = 0.009; BMI > 30; RR 1.49; p = 0.006), smoking (former smoker: RR 1.54; p < 0.0001; active smoker: RR 1.25; p < 0.0001), and frequent alcohol intake (RR 1.7; p = 0.003) were all associated with an increased risk of EAL following esophagectomy. We show that preoperative management targeting these risk factors result in a significant reduction of EAL.</p><p><strong>Conclusion: </strong>Our extensive review underscores the critical role of cardiovascular, pulmonary, and renal conditions in EAL development, emphasizing the importance of prehabilitation to mitigate risks associated with EAL after esophagectomy.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"132"},"PeriodicalIF":1.6,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12159115/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144275076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatic Yolk Sac Tumor: A Systematic Review of Presentation, Diagnosis, and Treatment.","authors":"Brittany Kwait, Awais Paracha, Umar Durrani, Michael Attanasi, Fahad Hussain, Jervon Wright, Amanda Lee, Anthony Papale, Veena John","doi":"10.1007/s12029-025-01250-8","DOIUrl":"https://doi.org/10.1007/s12029-025-01250-8","url":null,"abstract":"<p><strong>Purpose: </strong>Primary hepatic yolk sac tumor (HYST) is a rare, extragonadal germ cell neoplasm that arises in hepatic tissue. This review aims to examine clinical features, diagnostic workup, and medical and surgical interventions in patients diagnosed with primary HYST.</p><p><strong>Methods: </strong>A literature search was performed using PubMed from 1950 to June 2024 using the filters English language and full text along with keywords \"Yolk sac tumor of the liver,\" \"Endodermal Sinus tumor of liver,\" \"Hepatic Yolk sac tumor,\" and \"Hepatic Endodermal sinus tumor.\"</p><p><strong>Results: </strong>Our results examined 20 patients ranging from age 15 months to 64 years. The cases included 14 female and 6 male patients. The most common presenting symptom was abdominal pain in adults and abdominal distention in children. Upon histologic evaluation, Schiller-Duval bodies were seen in the majority of examined tumors. Commonly noted markers included alpha fetal protein, cytokeratin AE1/AE3, alpha-1 anti-trypsin, placental alkaline phosphatase, SALL4, and periodic acid-Schiff. Treatment options included chemotherapy, surgery, transplant, and trans-arterial chemoembolization.</p><p><strong>Conclusions: </strong>In this review, we discuss clinical signs of primary HYST. We highlight the importance of Schiller-Duval bodies on histology, as well as new markers in an attempt to aid in making a diagnosis of HYST.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"131"},"PeriodicalIF":1.6,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144266415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Essentials of Vitamin and Mineral Supplementation After Total Gastrectomy.","authors":"Rachael C Lopez, Amber F Gallanis, Jeremy L Davis","doi":"10.1007/s12029-025-01240-w","DOIUrl":"10.1007/s12029-025-01240-w","url":null,"abstract":"","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"130"},"PeriodicalIF":1.6,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12144039/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144234328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: The Association Between Health Literacy and Colorectal Cancer Screening: Findings Using a Three-Question Health Literacy Measure.","authors":"Alfonsus Adrian H Harsono, Rachel Ruiz, Meghna Katta, Hannah Ficarino Sheffer, Marshall Chandler McLeod, Smita Bhatia, Terry Davis, Daniel I Chu, Robert H Hollis","doi":"10.1007/s12029-025-01253-5","DOIUrl":"https://doi.org/10.1007/s12029-025-01253-5","url":null,"abstract":"","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"129"},"PeriodicalIF":1.6,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144234327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}